Feasibility and safety of platinum‑doublet therapy in patients with small‑cell lung cancer in the third‑line setting: <br />A multi‑institutional retrospective study

Fukushima,Takashi; Makiguchi,Tomonori; Tanaka,Yusuke; Chubachi,Kei; Ishidoya,Mina; Suzuki,Sachio; Tanaka,Hisashi; Taima,Kageaki; Hasegawa,Yukihiro; Okudera,Koichi; Tasaka,Sadatomo

doi:10.3892/ol.2022.13488

Feasibility and safety of platinum‑doublet therapy in patients with small‑cell lung cancer in the third‑line setting:
A multi‑institutional retrospective study

Authors:
- Takashi Fukushima
- Tomonori Makiguchi
- Yusuke Tanaka
- Kei Chubachi
- Mina Ishidoya
- Sachio Suzuki
- Hisashi Tanaka
- Kageaki Taima
- Yukihiro Hasegawa
- Koichi Okudera
- Sadatomo Tasaka
View Affiliations

Affiliations: Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036‑8562, Japan, Department of Respiratory Medicine, Aomori Prefectural Central Hospital, Aomori, Aomori 030‑8553, Japan, Department of Respiratory Medicine, Hirosaki Central Hospital, Hirosaki, Aomori 036‑8188, Japan
Published online on: September 1, 2022 https://doi.org/10.3892/ol.2022.13488
Article Number: 368
Copyright: © Fukushima et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Small‑cell lung cancer (SCLC) is a highly malignant tumor, and no standard third‑line therapy has been established. The present study retrospectively analyzed the efficacy and safety of platinum‑based regimens in patients with third‑line SCLC who received third‑line chemotherapy. The association of regimen type with overall survival (OS) or time to treatment failure (TTF) was evaluated using the Cox hazard proportional method, including well‑known covariates affecting the prognosis of SCLC. TTF and OS analyses were conducted using the Kaplan‑Meier method. The data cutoff date was June 30, 2020. As a result, from January 2015 to August 2019, 111 patients were diagnosed with SCLC, and 37 received third‑line chemotherapy. Subsequently, 15 patients received a platinum‑doublet regimen, and 22 patients received a single‑agent regimen. Only the type of regimen was significantly associated with TTF in univariate analysis (odds ratio, 0.44; 95% confidence interval, 0.20‑0.95; P=0.03). There were no significant factors associated with OS. The median TTF of patients receiving a platinum‑doublet regimen and those receiving a single‑agent regimen were 3.9 and 2.3 months, respectively (P=0.03). The overall response rates of the platinum‑doublet and single‑agent regimens were 20.0 and 4.5%, respectively. Similarly, the disease control rates were 73.3 and 36.4% for platinum‑doublet and single‑agent regimens, respectively. There was a tendency for adverse events (AEs) with any grade to occur more often in platinum‑based regimens compared with in single‑agent regimens. Severe AEs of grade 3 or higher were observed more often in the platinum‑based regimen, especially in myelosuppression. In conclusion, the present study demonstrated the feasibility and safety of platinum‑doublet regimens in patients with SCLC in a third‑line setting (Registration no. 2020‑048. Date of registration, June 5, 2020).

View Figures

View References

1	van Meerbeeck JP, Fennell DA and De Ruysscher DK: Small-cell lung cancer. Lancet. 378:1741–1755. 2011. View Article : Google Scholar : PubMed/NCBI
2	Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, et al: First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 379:2220–2229. 2018. View Article : Google Scholar : PubMed/NCBI
3	Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, et al: Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet. 394:1929–1939. 2019. View Article : Google Scholar : PubMed/NCBI
4	Kim YH, Goto K, Yoh K, Niho S, Ohmatsu H, Kubota K, Saijo N and Nishiwaki Y: Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy. Cancer. 113:2518–2523. 2008. View Article : Google Scholar : PubMed/NCBI
5	O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, Thatcher N, Ross GA, Dane GC and Crofts T: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 24:5441–5447. 2006. View Article : Google Scholar : PubMed/NCBI
6	von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, et al: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 17:658–667. 1999. View Article : Google Scholar : PubMed/NCBI
7	Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G and Ross G: Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 25:2086–2092. 2007. View Article : Google Scholar : PubMed/NCBI
8	Jotte R, Conkling P, Reynolds C, Galsky MD, Klein L, Fitzgibbons JF, McNally R, Renschler MF and Oliver JW: Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol. 29:287–293. 2011. View Article : Google Scholar : PubMed/NCBI
9	von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, et al: Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 32:4012–4019. 2014. View Article : Google Scholar : PubMed/NCBI
10	Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, et al: Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan lung cancer study group trial 0402. J Clin Oncol. 26:5401–5406. 2008. View Article : Google Scholar : PubMed/NCBI
11	Horita N, Yamamoto M, Sato T, Tsukahara T, Nagakura H, Tashiro K, Shibata Y, Watanabe H, Nagai K, Nakashima K, et al: Amrubicin for relapsed small-cell lung cancer: A systematic review and meta-analysis of 803 patients. Sci Rep. 6:189992016. View Article : Google Scholar : PubMed/NCBI
12	Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, et al: Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 17:1147–1157. 2016. View Article : Google Scholar : PubMed/NCBI
13	Wakuda K, Miyawaki T, Miyawaki E, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Nakashima K, Ono A, Kenmotsu H, et al: Efficacy of second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer. In Vivo. 33:2229–2234. 2019. View Article : Google Scholar : PubMed/NCBI
14	Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, et al: Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: An open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 21:1224–1233. 2020. View Article : Google Scholar : PubMed/NCBI
15	Murakami H, Yamamoto N, Shibata T, Takeda K, Ichinose Y, Ohe Y, Yamamoto N, Takeda Y, Kudoh S, Atagi S, et al: A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan clinical oncology group study (JCOG0901). Lung Cancer. 84:67–72. 2014. View Article : Google Scholar : PubMed/NCBI
16	Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J and Verweij J: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. The European organization for research and treatment of cancer early clinical studies group and new drug development office, and the lung cancer cooperative group. J Clin Oncol. 15:2090–2096. 1997. View Article : Google Scholar : PubMed/NCBI
17	Kondo R, Watanabe S, Shoji S, Ichikawa K, Abe T, Baba J, Tanaka J, Tsukada H, Terada M, Sato K, et al: A Phase II study of irinotecan for patients with previously treated small-cell lung cancer. Oncology. 94:223–232. 2018. View Article : Google Scholar : PubMed/NCBI
18	Horiuchi K, Sato T, Kuno T, Takagi H, Hirsch FR, Powell CA and Fukunaga K: Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 156:59–67. 2021. View Article : Google Scholar : PubMed/NCBI
19	Saruwatari K, Umemura S, Nomura S, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Ohe Y and Goto K: Prognostic factor analysis in patients with small-cell lung cancer treated with third-line chemotherapy. Clin Lung Cancer. 17:581–587. 2016. View Article : Google Scholar : PubMed/NCBI
20	Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, Spigel DR, Moreno V, Chau I, Hann CL, et al: Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol. 14:237–244. 2019. View Article : Google Scholar : PubMed/NCBI
21	Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, Audigier-Valette C, Pardo Aranda N, Juan-Vidal O, Cheng Y, et al: Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol. 32:631–641. 2021. View Article : Google Scholar : PubMed/NCBI